[
    [
        {
            "time": "",
            "original_text": "[领先大市-A评级]医药行业每周观点：关注业绩超预期及估值增速具备高性价比的投资机会 首推葵花药业和济川药业",
            "features": {
                "keywords": [
                    "医药行业",
                    "业绩超预期",
                    "估值增速",
                    "高性价比",
                    "葵花药业",
                    "济川药业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[领先大市-A评级]医药行业每周观点：关注业绩超预期及估值增速具备高性价比的投资机会 首推葵花药业和济川药业",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]